CALL US: 206.533.3854
CALL US  206.533.3854
AEON Law logo full color transparent

Is There Really a Patent Death Squad?

P.T.A.B. Chief
Says “death squad” label isn’t
Totally off-base

The Chief Judge of the Patent and Trademark Appeals Board (PTAB) has admitted that its reputation as a “death squad” for patents isn’t without merit. In a question-and-answer session last October at the annual meeting of the American Intellectual Property Law Association, former Federal Circuit Judge Randall Rader remarked that there was a tension inherent in the US Patent and Trademark Office, which both issues patents and can “kill” them via administrative hearings:

“There’s a tension throughout the system … you’ve got an agency with 7,000 people giving birth to property rights, and then you’ve got, in the same agency,  300 or so people on the back end … acting as death squads, kind of killing property rights.”

PTAB Chief Judge James Smith told the US Patent and Trademark Office’s Patent Public Advisory Committee that although the “death squad” label has been used by the PTAB’s critics, the term in some ways adequately describes the PTAB’s mission, given to it by Congress under the America Invents Act (AIA). Judge Smith said, “The purpose of the proceedings is to identify some limited number of patents and claims that are unpatentable and make sure the claims are removed. If we weren’t, in part, doing some ‘death squadding,’ we would not be doing what the statute calls on us to do.” He doesn’t even think that the “death squad” label is as negative as it may have been meant: “Clearly, the statistics show not every claim in a patent brought forward to the board has met its death because it has been raised in a petition.”

The PTAB’s “death rate” has been on the decline in the past year, possibly because some of the weakest patents were challenged – and “killed” – earlier in the process. In fiscal 2013, the PTAB instituted 167 reviews of previously granted patents and denied 26 of such petitions, for a review rate of 87%. It has since fallen to 76%.

The total number of requests for review has been growing, however. In June, the PTAB received what he called an “astronomical high” of 190 new petitions. The number fell to 120 in July – perhaps because many patent lawyers went on vacation. In about 41% of the inter partes review cases, the PTAB upheld at least some of the challenged patent claims – showing that “death” is far from certain.

A petition for inter partes review cannot be filed until after the later of:

· nine months after the grant of a patent or

· the date of termination of any post-grant review of the patent.

Thus, it’s important to act promptly if you want to have a “shot” at getting a patent invalidated via this procedure.

Related Articles

Patent and Trademark Offices Publish Study on NFT IP Issues

The US Patent and Trademark Office (USPTO) and the Copyright Office have published the results of their joint study on non-fungible tokens (NFTs) and intellectual property (IP). ...
Read More

Fourth Circuit Overturns $1 Billion Copyright Infringement Verdict

The Fourth Circuit has overturned a $1 billion verdict in a copyright case against Cox Communications. As the court explained, Defendant Cox Communications sells internet, ...
Read More

Will Federal Circuit Soften Test for Design Patent Obviousness?

An en banc panel of the Federal Circuit recently heard arguments in a case that could change how courts assess design patents for “obviousness.” LKQ ...
Read More

Let's work together.

Contact us to set up a meeting with an attorney or team member.

Stay Informed

Sign up to receive Patent Poetry—a monthly roundup of key IP issues in our signature haiku format. Four articles (only 68 syllables); zero hassle.

SECTORS

HIGH
TECHNOLOGY

Artificial Intelligence

Blockchain & Cryptocurrency

Computer Technology & Software

Consumer Electronics

Electrical Devices

MECHANICAL
& PRODUCTS​

Cleantech

Mechanical Devices

Consumer & Retail Products

Hardware & Tools

Toys & Games

LIFE SCIENCES
& CHEMISTRY​

Biotechnology

Chemical Compounds

Digital Health

Healthcare Products

Pharmaceuticals

BRANDING
& CREATIVE​

Books & Publications

Brand Creation

Luxury Products

Photography & Video

Product Design

SERVICES

PROTECT

DEAL

DEFEND